Kalshi to offer betting on drug trial results and FDA regulatory decisions

Kalshi, a US prediction market platform, has received regulatory approval to offer betting contracts on FDA drug trial outcomes and regulatory decisions. This opens a new asset class for traders to speculate on biotech and pharma development timelines and approval odds.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.